Chong Kun Dang Pharmaceutical Corp banner

Chong Kun Dang Pharmaceutical Corp
KRX:185750

Watchlist Manager
Chong Kun Dang Pharmaceutical Corp Logo
Chong Kun Dang Pharmaceutical Corp
KRX:185750
Watchlist
Price: 67 900 KRW 1.34% Market Closed
Market Cap: ₩937B

Wall St Price Targets

Price Targets Summary
Chong Kun Dang Pharmaceutical Corp

Wall Street analysts forecast Chong Kun Dang Pharmaceutical Corp stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Chong Kun Dang Pharmaceutical Corp is 120 214.29 KRW with a low forecast of 101 000 KRW and a high forecast of 162 750 KRW.

Lowest Forecast
Price Target
101 000 KRW
49% Upside
Average Forecast
Price Target
120 214.29 KRW
77% Upside
Highest Forecast
Price Target
162 750 KRW
140% Upside
Chong Kun Dang Pharmaceutical Corp Competitors:
Price Targets
M3C0
Mitsubishi Chemical Group Corp
-16% Downside
EVER
EverQuote Inc
1% Upside

Revenue
Forecast

11% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
11% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 10 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 6%.

Gross Profit
Forecast

6% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
6% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 10 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 7%.

Operating Income
Forecast

7% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
7% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 10 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 2 years is 3%.

Pre-Tax Income
Forecast

18% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
18% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 10 years, the compound annual growth rate for Pre-Tax Income has been 18%. The projected CAGR for the next 2 years is 7%.

Net Income
Forecast

N/A
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

The compound annual growth rate for Net Income over the next 2 years is 3%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Chong Kun Dang Pharmaceutical Corp's stock price target?
Price Target
120 214.29 KRW

According to Wall Street analysts, the average 1-year price target for Chong Kun Dang Pharmaceutical Corp is 120 214.29 KRW with a low forecast of 101 000 KRW and a high forecast of 162 750 KRW.

What is the Revenue forecast for Chong Kun Dang Pharmaceutical Corp?
Projected CAGR
6%

Over the last 10 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 6%.

What is the Gross Profit forecast for Chong Kun Dang Pharmaceutical Corp?
Projected CAGR
7%

Over the last 10 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 2 years is 7%.

What is the Operating Income forecast for Chong Kun Dang Pharmaceutical Corp?
Projected CAGR
3%

Over the last 10 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 2 years is 3%.

What is the Pre-Tax Income forecast for Chong Kun Dang Pharmaceutical Corp?
Projected CAGR
7%

Over the last 10 years, the compound annual growth rate for Pre-Tax Income has been 18%. The projected CAGR for the next 2 years is 7%.

What is the Net Income forecast for Chong Kun Dang Pharmaceutical Corp?
Projected CAGR
3%

The compound annual growth rate for Net Income over the next 2 years is 3%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett